Literature DB >> 2653214

Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and 3'-azido-3'-deoxythymidine.

V A Johnson1, B D Walker, M A Barlow, T J Paradis, T C Chou, M S Hirsch.   

Abstract

Castanospermine and 3'-azido-3'-deoxythymidine (zidovudine) were evaluated in combination against human immunodeficiency virus (HIV) replication in vitro. Castanospermine and 3'-azido-3'-deoxythymidine inhibited HIV type 1 synergistically in acutely infected H9 cells. In addition, they synergistically inhibited both HIV type 1 and HIV type 2 in peripheral blood mononuclear cells. There were no additional toxic effects of these agents in combination. Drug interactions were evaluated by the median-effect principle and the isobologram technique. Combinations of a glycosylation inhibitor, such as castanospermine, with 3'-azido-3'-deoxythymidine deserve consideration for HIV-related chemotherapeutic intervention.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2653214      PMCID： PMC171420          DOI： 10.1128/AAC.33.1.53

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

1.  Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

Authors:  J S Allan; J E Coligan; F Barin; M F McLane; J G Sodroski; C A Rosen; W A Haseltine; T H Lee; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

2.  Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.

Authors:  J Sodroski; W C Goh; C Rosen; K Campbell; W A Haseltine
Journal:  Nature       Date:  1986 Jul 31-Aug 6       Impact factor: 49.962

3.  Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.

Authors:  D D Ho; K L Hartshorn; T R Rota; C A Andrews; J C Kaplan; R T Schooley; M S Hirsch
Journal:  Lancet       Date:  1985-03-16       Impact factor: 79.321

4.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

5.  Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1.

Authors:  M W Vogt; A G Durno; T C Chou; L A Coleman; T J Paradis; R T Schooley; J C Kaplan; M S Hirsch
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

6.  Studies on the mechanism of castanospermine inhibition of alpha- and beta-glucosidases.

Authors:  R Saul; R J Molyneux; A D Elbein
Journal:  Arch Biochem Biophys       Date:  1984-05-01       Impact factor: 4.013

7.  Castanospermine inhibits the processing of the oligosaccharide portion of the influenza viral hemagglutinin.

Authors:  Y T Pan; H Hori; R Saul; B A Sanford; R J Molyneux; A D Elbein
Journal:  Biochemistry       Date:  1983-08-02       Impact factor: 3.162

8.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

9.  Castanospermine inhibits alpha-glucosidase activities and alters glycogen distribution in animals.

Authors:  R Saul; J J Ghidoni; R J Molyneux; A D Elbein
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

10.  HTLV-III in the semen and blood of a healthy homosexual man.

Authors:  D D Ho; R T Schooley; T R Rota; J C Kaplan; T Flynn; S Z Salahuddin; M A Gonda; M S Hirsch
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728
View more
  10 in total

Review 1.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.

Authors:  X B Kong; Q Y Zhu; R M Ruprecht; K A Watanabe; J M Zeidler; J W Gold; B Polsky; D Armstrong; T C Chou
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

4.  A high-throughput single-cell analysis of human CD8⁺ T cell functions reveals discordance for cytokine secretion and cytolysis.

Authors:  Navin Varadarajan; Boris Julg; Yvonne J Yamanaka; Huabiao Chen; Adebola O Ogunniyi; Elizabeth McAndrew; Lindsay C Porter; Alicja Piechocka-Trocha; Brenna J Hill; Daniel C Douek; Florencia Pereyra; Bruce D Walker; J Christopher Love
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

5.  Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.

Authors:  R E Dornsife; M H St Clair; A T Huang; T J Panella; G W Koszalka; C L Burns; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

6.  A new reporter cell line to monitor HIV infection and drug susceptibility in vitro.

Authors:  A Gervaix; D West; L M Leoni; D D Richman; F Wong-Staal; J Corbeil
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

7.  Anti-human immunodeficiency virus effects of dextran sulfate are strain dependent and synergistic or antagonistic when dextran sulfate is given in combination with dideoxynucleosides.

Authors:  M E Busso; L Resnick
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 8.  Antiviral therapy in human immunodeficiency virus infection.

Authors:  E Sandström
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

9.  Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: a pilot study.

Authors:  R Weber; A Bonetti; J Jost; M W Vogt; B Spacey; W Siegenthaler; R Lüthy
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

10.  Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.

Authors:  B D Walker; C Flexner; K Birch-Limberger; L Fisher; T J Paradis; A Aldovini; R Young; B Moss; R T Schooley
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.